ES8602407A1 - Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado - Google Patents

Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado

Info

Publication number
ES8602407A1
ES8602407A1 ES533901A ES533901A ES8602407A1 ES 8602407 A1 ES8602407 A1 ES 8602407A1 ES 533901 A ES533901 A ES 533901A ES 533901 A ES533901 A ES 533901A ES 8602407 A1 ES8602407 A1 ES 8602407A1
Authority
ES
Spain
Prior art keywords
component
cefaclor
enteric
release
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES533901A
Other languages
English (en)
Spanish (es)
Other versions
ES533901A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of ES8602407A1 publication Critical patent/ES8602407A1/es
Publication of ES533901A0 publication Critical patent/ES533901A0/es
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES533901A 1983-06-15 1984-06-15 Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado Granted ES533901A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58108289A JPS601128A (ja) 1983-06-15 1983-06-15 作用持続型セフアクロル製剤

Publications (2)

Publication Number Publication Date
ES8602407A1 true ES8602407A1 (es) 1985-12-01
ES533901A0 ES533901A0 (es) 1985-12-01

Family

ID=14480890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES533901A Granted ES533901A0 (es) 1983-06-15 1984-06-15 Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado

Country Status (23)

Country Link
US (1) US4713247A (en:Method)
EP (1) EP0129382B1 (en:Method)
JP (1) JPS601128A (en:Method)
KR (1) KR910004573B1 (en:Method)
AT (1) ATE56869T1 (en:Method)
AU (1) AU568654B2 (en:Method)
BG (1) BG60261B2 (en:Method)
CA (1) CA1213218A (en:Method)
DD (1) DD216163A5 (en:Method)
DE (1) DE3483282D1 (en:Method)
DK (2) DK291884A (en:Method)
ES (1) ES533901A0 (en:Method)
FI (1) FI84556C (en:Method)
GB (1) GB2141342B (en:Method)
GR (1) GR81598B (en:Method)
HU (1) HU193434B (en:Method)
IE (1) IE58278B1 (en:Method)
IL (1) IL72083A (en:Method)
NZ (1) NZ208345A (en:Method)
PH (1) PH19902A (en:Method)
PT (1) PT78699B (en:Method)
RO (1) RO88924A (en:Method)
ZA (1) ZA844357B (en:Method)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
JPH0714863B2 (ja) * 1986-06-02 1995-02-22 忠生 白石 時差溶解性の入浴剤
CA1316110C (en) * 1987-02-27 1993-04-13 Peter Lloyd Oren Sustained release matrix formulations
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
BE1002079A4 (fr) * 1988-07-01 1990-06-19 S M B Lab Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
AU8219191A (en) * 1990-06-14 1992-01-07 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
AU5107496A (en) * 1996-03-13 1997-10-01 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Medicament preparation for angiotensin converting enzyme (ace)-inhibitors
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) * 1998-01-29 1998-10-28 Ranbaxy Lab Ltd Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
WO2000059479A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
WO2000069417A1 (en) * 1999-05-14 2000-11-23 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
US6596307B1 (en) 1999-06-15 2003-07-22 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
AU2001239841B2 (en) * 2000-02-24 2006-04-27 Shionogi, Inc. Antibiotic and antifungal compositions
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
JP2003523378A (ja) * 2000-02-24 2003-08-05 アドバンシス ファーマシューティカル コーポレイション 治療剤製品、その使用及び製剤形態
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
AU3986901A (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2435305A1 (en) * 2001-01-18 2002-07-25 Natco Pharma Limited Extended release pharmaceutical compositions containing beta-lactam antibiotics
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
WO2003094899A1 (es) * 2002-05-09 2003-11-20 Diffucap-Chemobras Química E Farmacéutica, Ltda. Nuevo procedimiento para la preparacion de composiciones de liberacion programada conteniendo (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, y al producto obtenido por dicho procedimiento
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
BR0318535A (pt) * 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
CA2602268A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
US20060287212A1 (en) * 2005-06-02 2006-12-21 Novozymes A/S Blends of inactive particles and active particles
JP2008545841A (ja) 2005-06-02 2008-12-18 ノボザイムス アクティーゼルスカブ 不活性粒子及び活性粒子のブレンド
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PL3351240T3 (pl) 2009-05-19 2019-09-30 Celgene Corporation Preparaty 4-amino-2-(2,6-dioksopiperydyn-3-ylo)izoindolino-1,3-dionu
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104688701A (zh) * 2015-03-20 2015-06-10 江苏亚邦强生药业有限公司 一种头孢克洛片剂及其制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (en:Method) * 1980-08-27 1984-07-12 Ciba Geigy Ag
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤

Also Published As

Publication number Publication date
AU2941884A (en) 1984-12-20
EP0129382A2 (en) 1984-12-27
DK291884D0 (da) 1984-06-14
DK170922B1 (da) 1996-03-18
IE841444L (en) 1984-12-15
BG60261B1 (bg) 1994-03-31
GR81598B (en:Method) 1984-12-11
US4713247A (en) 1987-12-15
JPS601128A (ja) 1985-01-07
KR850000242A (ko) 1985-02-26
DK291884A (da) 1984-12-16
PT78699B (en) 1986-07-15
HUT34692A (en) 1985-04-28
PT78699A (pt) 1985-01-01
KR910004573B1 (ko) 1991-07-06
DD216163A5 (de) 1984-12-05
DE3483282D1 (de) 1990-10-31
GB2141342A (en) 1984-12-19
ATE56869T1 (de) 1990-10-15
JPS6232166B2 (en:Method) 1987-07-13
EP0129382A3 (en) 1986-07-09
GB2141342B (en) 1986-11-12
RO88924A (ro) 1986-04-30
ZA844357B (en) 1985-06-26
FI842406L (fi) 1984-12-16
GB8414633D0 (en) 1984-07-11
FI84556B (fi) 1991-09-13
ES533901A0 (es) 1985-12-01
IL72083A0 (en) 1984-10-31
IE58278B1 (en) 1993-08-25
CA1213218A (en) 1986-10-28
NZ208345A (en) 1986-12-05
HU193434B (en) 1987-10-28
PH19902A (en) 1986-08-13
IL72083A (en) 1987-10-30
EP0129382B1 (en) 1990-09-26
BG60261B2 (en) 1994-03-31
AU568654B2 (en) 1988-01-07
FI842406A0 (fi) 1984-06-13
FI84556C (fi) 1991-12-27

Similar Documents

Publication Publication Date Title
ES8602407A1 (es) Perfeccionamientos en los metodos de fabricacion del acido 3-cloro-7-d-(2-fenilglicinamido)-3-cefem-4-carboxilico monohidratado
US4740365A (en) Sustained-release preparation applicable to mucous membrane in oral cavity
ES8800041A1 (es) Un procedimiento para la produccion de una composicion farmaceutica de liberacion controlada de unidades individuales
CA1303504C (en) Pharmaceutical formulation containing acrivastine
ATE217188T1 (de) Granulierte pharmazeutische zusammensetzung
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
DK164259C (da) Farmaceutisk formulering til langsom frigivelse af den aktive bestanddel og fremgangsmaade til fremstilling af en saadan formulering
AU9072282A (en) Oral controlled release multiple unit formulation
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
ATE84705T1 (de) Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren.
ATE246505T1 (de) Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix
EP0103387A3 (en) Long-acting matrix tablet formulations
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
US4808416A (en) Preparation of a slow-release drug
US3865935A (en) Tableting of erythromycin base
JPH0157090B2 (en:Method)
GB1443923A (en) Sustained release compositions
PL180979B1 (pl) Sposób wytwarzania karbamazepinowej postaci lekarstwa z opóźnionym uwalnianiem substancji biologicznie czynnej
SE8701077L (sv) Farmaceutisk beredning
GB2190287A (en) Oral ketoprofen formulation
ES2019024A6 (es) Procedimiento de preparar una composicion farmaceutica a base de trimebutina.
JPS54126722A (en) Slow release antibiotic tablet
JPS56142208A (en) Prolongable prostaglandin transvaginal agent and its preparation
KR0177191B1 (ko) 테르페나딘 함유 펠렛 조성물
TH5189A (th) สารกระตุ้นความเจริญเติบโตของสัตว์